Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis Practice Advisory
Neurol 98:486-498, Turan, T.N.,et al, 2022
Moyamoya Disease and Moyamoya Syndrome
NEJM 360:1226-1237, Scott,R.M. &Smith,E.R., 2009
Treatment of Atherosclerotic Intracranial Arterial Stenosis
Stroke 40:2257-2261, Turan,T.N.,et al, 2009
Outcome of Symptomatic Intracranial Atherosclerotic Disease
Stroke 40:2983-2987, Samaniego,E.,et al, 2009
Intracranial Atherosclerotic Disease: An Update
Ann Neurol 66:730-738, Qureshi,A.,et al, 2009
Progress in Secondary Stroke Prevention
Ann Neurol 63:418-427, Romano,J.G. &Sacco,R.L., 2008
Warfarin vs Aspirin for Symptomatic Intracranial Stenosis: Subgroup Analyses from WASID
Neurol 67:1275-1278, Kasner,S.E.,et al, 2006
Comparison of Warfarin and Aspirin for Symptomatic Intracranial Arterial Stenosis
NEJM 352:1305-1316, 1368, Chimowitz,M.I.,et al, 2005
Symptomatic Intracranial Atherosclerosis
Neurol 55:490-497, 465, Thijs,V.N. & Albers,G.W., 2000
Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients with Atrial Cardiopathy, The ARCADIA Randomized Clinical Trial
JAMA 331:573-581, Kamel,H.,et al, 2024
Cortical Superficial Siderosis and Transient Focal Neurological Episode Preceding Lobar Hemorrhage in Cerebral Amyloid Angiopathy
Stroke 54:e48-e51, Therdorou,A.,et al, 2023
Antithrombotic Therapy in Patients with Cerebral Microbleeds or Cortical Siderosis, Is This Contraindicated?
Neurol 100:551-552, Schneck,M.J., &Biller,J., 2023
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion
NEJM 388:2025-2095, Zi,W.,et al, 2023
Antiplatelet Therapy or Not for Asymptomatic/Incidental Lacunar Infarction
Stroke 54:1954-1959, Bilski.A.,et al, 2023
Perioperative Management of Anticoagulant and Antiplatelet Therapy
NEJM Evid doi:10.1056/EVIDna2200322, Douketis,J.D. & Spyropoulos,A.C., 2023
Coagulation Factor Expression and Composition of Arterial Thrombi in Cancer-Associated Stroke
Stroke 54:2981-2989, Yoo,J.,et al, 2023
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
Bleeding Risk of Dual Antiplatelet Therapy after Minor Stroke or Transient Ischemic Attack
Ann Neurol 91:380-388, Wang, A.,et al, 2022
Oral Antiplatelet Therapy for Acute Ischemic Stroke
Stroke 53:e453-e454, Minhas, J.S.,et al, 2022
Cerebral Microbleeds
Stroke 52:2347-2355, Graff-Radford, J.,et al, 2021
Use of Dual Antiplatelet Therapy Following Ischemic Stroke
Stroke 51:e78-e80, Dong, J.,et al, 2020
Dabigatran Reversal Before Intravenous Tenecteplase in Acute Ischemic Stroke
Stroke 51:1616-1619, Beharry, J.,et al, 2020
Practice Advisory Update Summary: Patent Foramen Ovale and Secondary Stroke Prevention
Neurol 94:876-885, Messe, S.R.,et al, 2020
Transient Ischemic Attack
NEJM 382:1933-1941, Amarenco, P., 2020
Antiplatelet Treatment to Prevent Early Recurrent Stroke
NEJM 383:276-278, Rothwell, P.M., 2020
Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source
NEJM 380:1906-1917, Diener, H.C.,et al, 2019
Antiplatelet Therapy vs Anticoagulation Therapy in Cervical Artery Dissection
JAMA Neurol 76:657-664, Markus, H.S.,et al, 2019
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared with Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke
JAMA Neurol 76:774-782, Tillman, H.,et al, 2019
Antiplatelet and Anticoagulant Agents for Secondary Prevention of Thromboembolic Events in People with Antiphospholipid Syndrome
Stroke 49:e41-e42, Bala, M.M.,et al, 2018
Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA
NEJM 379:215-225, 291, Johnston, S.C.,et al, 2018
Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Dual Antiplatelet Therapy with Aspirin and Clopidogrel for Acute High Risk Transient Ischaemic Attack and Minor Ischaemic Stroke: A Clinical Practice Guideline
BMJ 363:k5130, Prasad, K.,et al, 2018
Pregnancy, Hormonal Treatments for Infertility, Contraception, and Menopause in Women After Ischemic Stroke
Stroke 48:501-506, Caso, V.,et al, 2017
Association of Antithrombotic Drug Use with Subdural Hematoma Risk
JAMA 317:836-846, Gaist, D.,et al, 2017
Anticoagulant and Antiplatelet Use in Seniors with Chronic Subdural Hematoma
Neurol 88:1889-1893, Nathan, S.,et al, 2017
Older Patients Should Take PPIs to Cut Risk of Bleed From Aspirin, Study Says
BMJ 357:J2865, Mayor, S., 2017
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
NEJM 377:1022-1032,1006,1093, Saver, J.L.,et al, 2017
Patent Foramen Ovale Closure or Anticoagulation Vs. Antiplatelets after Stroke
NEJM 377:1011-1021,1006,1093, Mas, J.L,et al, 2017
Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke
NEJM 377:1033-1042,1006,1093, Sondergaard, L.,et al, 2017
Embolic Stroke, Atrial Fibrillation, and Microbleeds
Stroke 47:904-907, Diener, H-C.,et al, 2016
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome
Ann Neurol 79:560-568, Park, J.M.,et al, 2016
Closure Versus Medical Therapy for Preventing Recurrent Stroke in Patients with Patent Foramen Ovale and a History of Cryptogenic Stroke or Transient Ischemic Attack
Stroke 47:e188-e189, Li, J.,et al, 2016
Ticagrelor Versus Aspirin in Acute Stroke or Transient Ischemic Attack
NEJM 375:35-43, Johnston, S.C.,et al, 2016
Platelet Transfusion versus Standard Care after Acute Stroke Due to Spontaneous Cerebral Haemorrhage Associated with Antiplatelet Therapy (PATCH): A Randomised, Open-Label, Phase 3 Trial
Lancet 387:2605-2613, Baharoglu, M.,et al, 2016
Effects of Aspiring on Risk and Severity of Early Recurrent Stroke After Transient Ischaemic Attack and Ischaemic Stroke: Time-Course Analysis of Randomised Trials
Lancet: 388:365-375, 312, Rothwell, P.M.,et al, 2016
Primary Prevention of Stroke
JAMA 316:658-659, Steiger, N. & Cifu, A.S., 2016
Stroke Outcomes with use of Antithrombotics within 24 hours after Recanalization Treatment
Neurol 87:996-1002, Jeong, H.G.,et al, 2016
Efficacy of Antiplatelet Therapy in Secondary Prevention Following Lacunar Stroke
Stroke 46:1014-1023, Kwok, C.S.,et al, 2015